Journal of Substance Abuse Treatment
Volume 30, Issue 1 , Pages 39-47 , January 2006

Outpatient substance abuse treatment and HIV prevention: An update

  • Harold A. Pollack, Ph.D.

      Affiliations

    • University of Chicago, Chicago, IL 60637, USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • Thomas D'Aunno, Ph.D.

      Affiliations

    • INSEAD, 77305 Fontainebleau Cedex, France
    • ,
  • Barbara Lamar, Ph.D.

      Affiliations

    • Institute for Social Research, University of Michigan, Ann Arbor, MI, USA

Received 3 November 2004 ,Revised 21 September 2005 ,Accepted 27 September 2005.

References 

  1. Adams TA, Heeringa SG. Outpatient Substance Abuse Treatment System Surveys (OSATSS): Technical documentation for OSATSS-5, 1999–2000. Ann Arbor: Institute for Social Research, Survey Design and Analysis Unit, University of Michigan; 2001;
  2. Avins A, Lindan C, Woods W, Hudes E, Boscarino J, Kay J, et al. Changes in HIV-related behaviors among heterosexual alcoholics following addiction treatment. Drug and Alcohol Dependence. 1997;44:47–55
  3. Ball J, Lange W, Myers C, Friedman S. Reducing the risk of AIDS through methadone maintenance treatment. Journal of Health and Social. 1988;214–226
  4. Ball JC, Ross A. The effectiveness of methadone maintenance treatment: Patients, programs, services, and outcome. New York: Springer-Verlag; 1991;
  5. Barnett P. The cost–effectiveness of methadone maintenance as a health care intervention. Addiction. 1999;94:479–488
  6. Batten H, Prottas J, Horgan C, Simon L, Larson M, Elliot E, et al. Drug Services Research Survey, final report: Phase II. Waltham, MA: Institute for Health Policy. Brandeis University; 1992;
  7. CDC . Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Morbidity and Mortality Weekly Report. 1998;47:1–39
  8. CDC . Drug-associated HIV transmission continues in the United States. Atlanta, GA: Centers for Disease Control and Prevention; 2002;
  9. CDC . Basic statistics. In: Atlanta, GA: National Center for HIV, STD and TB Prevention Divisions of HIV/AIDS Prevention; 2003;
  10. CDC . Incorporating HIV prevention into the medical care of persons living with HIV. Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society. Morbidity and Mortality Weekly Report. 2003;52:1–24
  11. Choi K, Coates T. Prevention of HIV infection. AIDS. 1994;8:1371–1389
  12. Coyle S, Needle R, Normand J. Outreach-based HIV prevention for injection drug users: A review of published outcome data. Public Health Reports. 1998;113:4–18
  13. Coutinho R. HIV and hepatitis C among injecting drug users: Success in preventing HIV has not been mirrored for hepatitis C. British Medical Journal. 1998;317:424–425
  14. Crofts N, Hopper J, Milner R, Breschkin A, Bowden D, Locarnini S. Blood-borne virus infections among Australian injecting drug users: Implications for spread of HIV. European Journal of Epidemiology. 1994;10:687–694
  15. Crofts N, Nigro L, Oman K, Stevenson E, Sherman J. Methadone maintenance and hepatitis C virus infection among injecting drug users. Addiction. 1997;92:999–1005
  16. D'Aunno T, Folz-Murphy N, Lin X. Changes in methadone treatment practices: Results from a panel study, 1988–1995. American Journal of Drug and Alcohol Abuse. 1999;25:681–699
  17. D'Aunno T, Pollack HA. Changes in methadone treatment practices: Results from a national panel study, 1988–2000. Journal of the American Medical Association. 2002;288:850–856
  18. D'Aunno T, Vaughn T. Variations in methadone treatment practices: Results from a national study. Journal of the American Medical Association. 1992;267:253–258
  19. D'Aunno T, Vaughn T, McElroy P. An institutional analysis of HIV prevention efforts by the nation's outpatient drug abuse treatment units. Journal of Health and Social Behavior. 1999;40:175–192
  20. Des Jarlais D, Hagan H, Friedman S, Friedmann P, Goldberg D, Frisher M, et al. Maintaining low HIV prevalence in populations of injecting drug users. Journal of the American Medical Association. 1995;274:1226–1231
  21. Diggle P, Liang K, Zeger S. Analysis of longitudinal data. Oxford, UK: Oxford University Press; 1994;
  22. In:  Farrell M editors. Drug prevention: A review of the legislation, regulation and delivery of methadone in 12 member states of the European Union. London, England: National Addiction Center; 1995;
  23. Garfein R, Doherty M, Monterroso E, Thomas D, Nelson K, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young injection drug users. Journal of Acquired immune Deficiency Syndromes and Human Retrovirology. 1998;18:S11–S19
  24. Gottheil E, Lundy A, Weinstein S, Sterling R. Does intensive outpatient cocaine treatment reduce AIDS risky behaviors?. Journal of Addictive Diseases. 1998;17:61–69
  25. Groves R, Biemer PP, Lyberg L, Massey J, Nicholls W, Waksberg J. Telephone survey methodology. New York: Wiley; 1988;
  26. Hammett TM, Gaiter JL, Crawford C. Reaching seriously at-risk populations: Health interventions in criminal justice settings. Health Education and Behavior. 1998;25:99–120
  27. Heeringa SG. Outpatient drug abuse treatment studies: Technical documentation. Ann Arbor: Institute for Social Research, University of Michigan; 1996;
  28. Heimer R, Kaplan E, Khoshnood K, Jariwala B, Cadman E. Needle exchange decreases the prevalence of HIV-1 proviral DNA in returned syringes in New Haven, Connecticut. American Journal of Medicine. 1993;95:214–220
  29. Holtgrave D, Qualls N, Graham J. Economic evaluation of HIV prevention programs. Annual Review of Public Health. 1996;17:467–488
  30. Holtgrave D, Reiser W, Di Franciesco W. The evaluation of HIV counseling-and-testing services. Making the most of limited resources. AIDS Education and Prevention. 1997;9:105–118
  31. In:  Holtgrave DR editors. Handbook of HIV prevention policy analysis. New York: Plenum; 1998;
  32. Holtgrave DR, Kelly JA. Preventing HIV/AIDS among high-risk urban women: The cost–effectiveness of a behavioral group intervention. American Journal of Public Health. 1996;86:1442–1445
  33. IOM . Preventing HIV transmission: The role of sterile needles and bleach. Washington, DC: Institute of Medicine, National Academy Press; 1995;
  34. IOM . No time to lose: Making the most of HIV prevention. Washington, DC: National Academy Press; 2000;
  35. Kahn JG. The cost–effectiveness of HIV prevention targeting: How much more bang for the buck. American Journal of Public Health. 1996;86:1709–1712
  36. Kaplan EH, Pollack HA. Allocating HIV prevention resources. Socio-Economic Planning Sciences. 1998;32:257–263
  37. Langendam M, van Brussel G, Coutinho R, van Ameijden E. Methadone maintenance and cessation of injecting drug use: Results from the Amsterdam Cohort Study. Addiction. 2000;95:591–600
  38. Lemak C. (1998). Managed care and outpatient substance abuse treatment: A study of organizational response to external environments. Doctoral dissertation. Ann Arbor, MI: University of Michigan.
  39. Little R, Rubin D. Statistical analysis with missing data. New York: Wiley-Interscience; 2002;
  40. Metzger D, Navaline H. HIV prevention among injection drug users: The need for integrated models. Journal of Urban Health. 2003;80:iii59–iii66
  41. Metzger D, Navaline H. Human immunodeficiency virus prevention and the potential of drug abuse treatment. Clinical Infectious Diseases. 2003;37:S451–S456
  42. Metzger D, Navaline H, Woody GE. Drug abuse treatment as AIDS prevention. Public Health Reports. 1998;113:97–106
  43. Metzger D, Woody G, McLellan A, O'Brien C, Druley P, Navaline H, et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: An 18-month prospective follow-up. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1993;6:1049–1056
  44. Needle RH, Coyle S, Normand J, Lambert E, Cesar H. HIV prevention with drug-using populations—Current status and future prospects: Introduction and overview. Public Health Reports. 1998;113:4–18
  45. Pollack HA. Cost–effectiveness of harm reduction in preventing hepatitis C among injection drug users. Medical Decision Making. 2001;21:357–367
  46. Pollack HA. Methadone treatment as HIV prevention: Cost–effectiveness analysis. In:  Kaplan EH,  Brookmeyer R editor. Quantitative evaluation of HIV prevention programs. New Haven, CT: Yale University Press; 2002;p. 118–143
  47. Pollack HA. The challenge and future of HIV prevention. Journal of Health Politics, Policy, and Law. 2002;27:111–121
  48. Pollack HA, Heimer R. The impact and cost–effectiveness of methadone maintenance treatment in preventing HIV and hepatitis C. In:  Wiessing L editors. Impact and costs of hepatitis C in injecting drug users in the European Union. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2004;p. 345–370
  49. Rahman M, Fukui T, Asai A. Cost–effectiveness analysis of partner notification program for human immunodeficiency virus infection in Japan. Journal of Epidemiology. 1998;8:123–128
  50. Reback C, Larkins S, Shoptaw S. Changes in the meaning of sexual risk behaviors among gay and bisexual male methamphetamine abusers before and after drug treatment. AIDS and Behavior. 2004;8:87–98
  51. Shoptaw S, Frosch D, Rawson R, Ling W. Cocaine abuse counseling as HIV prevention. AIDS Education and Prevention. 1997;9:511–520
  52. Somlai A, Kelly J, McAuliffe T, Ksobiech K, Hackl K. Predictors of HIV sexual risk behaviors in a community sample of injection drug-using men and women. AIDS and Behavior. 2003;7:383–393
  53. van Empelen P, Kok G, van Kesteren N, van den Borne B, Bos A, Schaalma H. Effective methods to change sex-risk among drug users: A review of psychosocial interventions. Social Science and Medicine. 2003;57:1593–1608
  54. Vaughn TE. (1993). Methadone treatment practices and outcomes associated with them: An application of institutional theory [dissertation]. Ann Arbor: University of Michigan.
  55. Wheeler J, Nahra T. Private and public ownership in outpatient substance abuse treatment: Do we have a two-tiered system?. Administration and Policy in Mental Health. 2000;27:197–209
  56. Zaric GS, Brandeau ML, Barnett PG. Methadone maintenance and HIV prevention: A cost–effectiveness analysis. American Journal of Public Health. 2000;90:1100–1111

PII: S0740-5472(05)00196-0

doi: 10.1016/j.jsat.2005.09.002

Journal of Substance Abuse Treatment
Volume 30, Issue 1 , Pages 39-47 , January 2006

Article Tools